Abstract

Objectives: To develop and validate a predictive model for discriminating clinically significant prostate cancer (csPCa) from clinically insignificant prostate cancer (ciPCa).Methods: This retrospective study was performed with 159 consecutively enrolled pathologically confirmed PCa patients from two medical centers. The dataset was allocated to a training group (n = 54) and an internal validation group (n = 22) from one center along with an external independent validation group (n = 83) from another center. A total of 1,188 radiomic features were extracted from T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images derived from DWI for each patient. Multivariable logistic regression analysis was performed to develop the model, incorporating the radiomic signature, ADC value, and independent clinical risk factors. This was presented using a radiomic nomogram. The receiver operating characteristic (ROC) curve was utilized to assess the predictive efficacy of the radiomic nomogram in both the training and validation groups. The decision curve analysis was used to evaluate which model achieved the most net benefit.Results: The radiomic signature, which was made up of 10 selected features, was significantly associated with csPCa (P < 0.001 for both training and internal validation groups). The area under the curve (AUC) values of discriminating csPCa for the radiomics signature were 0.95 (training group), 0.86 (internal validation group), and 0.81 (external validation group). Multivariate logistic analysis identified the radiomic signature and ADC value as independent parameters of predicting csPCa. Then, the combination nomogram incorporating the radiomic signature and ADC value demonstrated a favorable classification capability with the AUC of 0.95 (training group), 0.93 (internal validation group), and 0.84 (external validation group). Appreciable clinical utility of this model was illustrated using the decision curve analysis for the nomogram.Conclusions: The nomogram, incorporating radiomic signature and ADC value, provided an individualized, potential approach for discriminating csPCa from ciPCa.

Highlights

  • Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide [1]

  • This study developed and validated a radiomic nomogram for discriminating between clinically significant PCa (csPCa) and clinically insignificant PCa (ciPCa) in the present study

  • The nomogram was constructed by containing the radscore from the radiomic method and apparent diffusion coefficient (ADC) value

Read more

Summary

Introduction

Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide [1]. If a patient presents with an elevated PSA, transrectal ultrasound (TRUS)guided biopsy is the conventional diagnostic approach. About over 30% of men undergo side effects with TRUS-guided biopsy, including pain, bleeding infection, and hematuria, and ∼1% need to be hospitalized for observation [3]. Some patients experience unnecessary biopsies as clinically insignificant PCa (ciPCa), defined as a Gleason score (GS)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call